Aquestive Therapeutics, Inc. (AQST) 2024 Q4 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Good day and thank you for standing by. Welcome to the fourth-quarter 2024 Aquestive Therapeutics earnings conference call. (Operator Instructions) Please be advised today's conference is being recorded.

    大家好,感謝您撥冗等候。歡迎參加 Aquestive Therapeutics 2024 年第四季財報電話會議。(接線員指示) 請注意,今天的會議將被錄音。

  • I would now like to hand the conference over to your speaker today, Brian Korb. Please go ahead.

    現在我想將會議交給今天的講者 Brian Korb。請開始。

  • Brian Korb - Investor Relations

    Brian Korb - Investor Relations

  • Thank you, operator. Good morning, and welcome to today's call. On today's call, I'm joined by Dan Barber, Chief Executive Officer; and Ernie Toth, Chief Financial Officer. We are going to provide an overview of recent business developments and performance for the fourth quarter year ended 2024 followed by a Q&A session. During the Q&A session, the team will be joined by Dr. Carl Kraus, Chief Medical Officer; Dr. Stephen Wargacki, Chief Science Officer; and Sherry Korczynski, Senior Vice President, Sales and Marketing.

    謝謝,接線員。各位早安,歡迎參加今天的電話會議。今天與我一同出席的有執行長 Dan Barber,以及財務長 Ernie Toth。我們將先概述近期業務進展,以及截至 2024 年度第四季與全年表現,之後進行問答環節。在問答環節中,團隊也將加入首席醫務官 Carl Kraus 醫師、首席科學官 Stephen Wargacki 醫師,以及銷售與行銷資深副總裁 Sherry Korczynski。

  • As a reminder, the company's remarks today correspond with the earnings release that was issued after market close yesterday. In addition, a recording of today's call will be made available on Aquestive's website within the Investors section shortly following the conclusion of this call.

    提醒各位,公司今天的發言與昨日收盤後發布的財報新聞稿相對應。此外,今天會議的錄音將在本次電話會議結束後不久,於 Aquestive 官網「投資人」專區提供。

  • To remind you, the Aquestive team will be discussing some non-GAAP financial measures this morning as part of its review of fourth quarter and year-end 2024 results. A description of these measures, along with a reconciliation to GAAP, can be found in the earnings release issued yesterday, which is posted on the Investors section of Aquestive's website.

    再次提醒,今天上午在回顧 2024 年第四季與全年業績時,Aquestive 團隊將討論部分非 GAAP 財務衡量指標。這些指標的說明以及與 GAAP 的調節表,可在昨日發布並張貼於 Aquestive 官網「投資人」專區的財報新聞稿中查閱。

  • During the call, the company will make some forward-looking statements. We remind you of the company's safe harbor language as outlined in yesterday's earnings release as well as the risks and uncertainties affecting the company as described in the Risk Factors section and other sections included in the company's annual report on Form 10-K filed with the Securities and Exchange Commission on March 5, 2025. As with any pharmaceutical company with product candidates under development and products being commercialized, there are significant risks and uncertainties with respect to the company's business and the development regulatory approval and commercialization of its products and other matters related to operations.

    在本次電話會議中,公司將作出若干前瞻性陳述。我們提醒各位注意公司在昨日財報新聞稿中所載的「安全港」聲明,以及公司於 2025 年 3 月 5 日向美國證券交易委員會提交之 Form 10-K 年報中「風險因素」章節及其他章節所述、影響公司的風險與不確定性。如同任何正在開發候選產品並推動產品商業化的製藥公司一樣,就公司業務、產品開發、監管核准與商業化,以及其他營運相關事項而言,均存在重大風險與不確定性。

  • Given these uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. Actual results may differ materially from these statements. All forward-looking statements attributable to Aquestive or any person acting on its behalf are expressly qualified in their entirety by this cautionary statement and the cautionary statements contained in the earnings release issued yesterday. The company assumes no obligation to update its forward-looking statements after the date of this conference call, whether as a result of new information, future events or otherwise, except as required under applicable law.

    鑑於上述不確定性,您不應過度依賴這些前瞻性陳述;其僅反映作出陳述當日的情況。實際結果可能與這些陳述存在重大差異。所有可歸因於 Aquestive 或任何代表其行事之人士的前瞻性陳述,均在整體上明確受本項警示聲明以及昨日發布之財報新聞稿中所載警示聲明的限制與約束。除非適用法律另有要求,公司不承擔在本次電話會議日期之後更新其前瞻性陳述的任何義務,不論係因新資訊、未來事件或其他原因所致。

  • Now, I would like to turn the call over to Dan.

    現在,我想把電話會議交給 Dan。

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • Thanks, Brian. I am thrilled to announce today that we have begun the filing process with the FDA for approval of our Anaphylm epinephrine sublingual film application. We will complete this application process over the next several weeks and expect the next major milestone for this program, the acceptance of the NDA sometime in June. This puts us on track to launch Anaphylm, if approved by the FDA, right on schedule in the first quarter of 2026. Today represents the achievement of a major milestone for our company, colleagues and stakeholders. This achievement was years in the making by scores of dedicated people who've focused their energy on making an impact on patients' lives. I am incredibly proud of and humbled by the achievements of these individuals.

    謝謝,Brian。我非常高興在今天宣布,我們已開始向 FDA 提交 Anaphylm 腎上腺素舌下薄膜申請的送件流程,以取得核准。我們將在接下來幾週完成此申請流程,並預期本計畫下一個重要里程碑——NDA 受理——將在 6 月的某個時間點達成。這使我們得以按計畫推進:若 Anaphylm 獲 FDA 核准,我們將可如期於 2026 年第一季上市。今天對我們公司、同仁與利害關係人而言,是達成一項重大里程碑。這項成果是多年努力的結晶,許多投入且敬業的人士將心力聚焦於為病患生活帶來影響。我對這些個人的成就感到無比自豪,也深感謙卑。

  • For almost three years, you've heard me talk about what we believe patients need in order to be better prepared for a severe allergic reaction, including anaphylaxis. We believe an epinephrine product that is carried more often will save lives. We believe epinephrine, that is orally administered, may be more likely to be used and used quickly and will save lives. We believe that speed matters when it comes to epinephrine absorption, and fast and significant absorption will save lives. Anaphylm was built to meet these needs and because of this, we believe patients will ultimately choose Anaphylm as their preferred product. Our plan is that less than a year from now, Anaphylm will be approved and available for patient use. This is truly an exciting time for the company.

    將近三年來,各位都聽我談到我們認為病患為了更好地因應嚴重過敏反應(包括過敏性休克)所需要的條件。我們相信,一款更常被隨身攜帶的腎上腺素產品將能拯救生命。我們相信,口服給藥的腎上腺素可能更容易被使用、也更可能被迅速使用,並將拯救生命。我們相信,就腎上腺素吸收而言,速度至關重要;快速且顯著的吸收將拯救生命。Anaphylm 的設計正是為了滿足這些需求,因此我們相信病患最終會選擇 Anaphylm 作為其偏好的產品。我們的計畫是,在不到一年的時間內,Anaphylm 將獲核准並可供病患使用。這對公司而言確實是一個令人振奮的時刻。

  • I am also pleased to announce today that our pediatric study for Anaphylm has progressed as expected. Our NDA will include the necessary pediatric data to support a product label that, if approved by the FDA, would mirror the weight and age parameters of the existing 0.3 milligram EpiPen auto-injector. Our pediatric data is in line with expectations, and we are wrapping up the final pediatric study activities over the coming days. We believe that this will conclude all the information that will be necessary for filing our NDA for Anaphylm.

    我也很高興在今天宣布,我們針對 Anaphylm 的兒科研究已如預期推進。我們的 NDA 將納入必要的兒科數據,以支持一項產品標示;若獲 FDA 核准,其體重與年齡參數將可比照現有 0.3 毫克 EpiPen 自動注射器。我們的兒科數據符合預期,且我們將在未來幾天完成最後的兒科研究相關工作。我們相信,這將完成提交 Anaphylm NDA 所需的全部資訊。

  • In addition, we have begun preparing for a potential advisory committee meeting for Anaphylm. As you may remember, our FDA pre-NDA meeting notes from November indicate that the FDA may decide to hold an advisory committee meeting. If this were to happen, we would expect it to occur in the second half of 2025. We have hired an experienced regulatory communications firm to aid us in our preparations, and we expect to be ready well in advance of the potential meeting.

    此外,我們已開始為 Anaphylm 可能召開的諮詢委員會會議做準備。如各位所記得,我們 11 月的 FDA pre-NDA 會議紀要顯示,FDA 可能會決定召開諮詢委員會會議。若確實發生,我們預期將在 2025 年下半年舉行。我們已聘請一家具經驗的法規溝通顧問公司協助準備,並預期能在潛在會議之前很早就做好充分準備。

  • Now, let's turn to our sales and marketing preparations for Anaphylm. We recently conducted an awareness, trial and usage, or ATU study, regarding anaphylaxis in Anaphylm. While this work is always a critical component of preparing for launch, we felt it was especially important since the non-needle nasal spray became available to the public over five months ago. In this study, on an aided basis, 92% of the 125 physicians that were interviewed were aware of the FDA-approved nasal spray product. Roughly 65% of these physicians had already written a prescription for the nasal spray.

    接下來談談我們為 Anaphylm 所做的銷售與行銷準備。我們近期針對過敏性休克與 Anaphylm 進行了一項認知度、試用與使用(awareness, trial and usage,ATU)研究。雖然這類工作一向是上市準備的關鍵組成,但我們認為在無針鼻噴劑於五個多月前開始向大眾提供後,這項研究尤其重要。在本研究中,在提示情境下,受訪的 125 位醫師中有 92% 知悉該款已獲 FDA 核准的鼻噴劑產品。約 65% 的醫師已經開立過該鼻噴劑的處方。

  • Yet when asked to allocate their potential future prescribing habits between auto-injectors, nasal sprays and sublingual film, film received a higher percentage than both the auto-injectors and nasal spray. While I generally view survey data as just directional, I believe, it is powerful that physicians who are aware of and have prescribed the existing nasal spray would still list sublingual film as their preferred most prescribed product under the theoretical premise that film was FDA approved and available to patients. This is before we have done the significant awareness work and marketing efforts that occurred after approval.

    然而,當被要求在自動注射器、鼻噴劑與舌下薄膜之間分配其未來可能的處方開立習慣時,薄膜所獲比例高於自動注射器與鼻噴劑兩者。雖然我通常將調查數據視為方向性參考,但我認為很有力的一點是:那些已知悉並曾開立現有鼻噴劑的醫師,在「假設薄膜已獲 FDA 核准且可供病患使用」的理論前提下,仍會將舌下薄膜列為其偏好且最可能大量開立的產品。而這還是在我們尚未於核准後展開大規模認知推廣與行銷投入之前。

  • Now, let's turn to commercialization. We believe there are multiple pathways to commercializing Anaphylm, if approved by the FDA. We continue to prepare for launching Anaphylm on our own, and most recently, hired in-house market access expertise to further drive our ongoing discussions with payers. This is in addition to the medical affairs awareness work we have been conducting, including increasing our medical publications, posters and presence at regional and national medical conferences. This work will intensify in the coming quarters as well our commercial preparation. As a reminder, our plan remains to obtain FDA approval prior to hiring a sales force.

    現在,讓我們談談商業化。我們相信,若 Anaphylm 獲 FDA 核准,將有多種商業化途徑。我們持續為自行推出 Anaphylm 做準備,並在最近聘請內部市場准入(market access)專才,以進一步推動我們與付款方(payers)的持續討論。此外,我們也持續進行醫藥事務(medical affairs)的認知推廣工作,包括增加醫學論文發表、海報展示,以及在區域性與全國性醫學會議上的曝光。未來幾季,這些工作以及我們的商業化準備都將加速推進。提醒各位,我們的計畫仍是:在聘用銷售團隊之前先取得 FDA 核准。

  • Another pathway for us to commercialize Anaphylm, if approved by the FDA, would be to augment our commercial capabilities with a larger, more established sales and marketing organization. This is something that we are actively contemplating, but will only do if the conditions are right for our company. These conditions, at a minimum, include working with a company that has the size and scale to truly expand our engagement efforts and a true commitment to patients in this therapeutic area. Only time will tell what the right path is for Anaphylm.

    若獲 FDA 核准,我們商業化 Anaphylm 的另一條途徑,是透過與規模更大、更加成熟的銷售與行銷組織合作,以強化我們的商業能力。這是我們正在積極評估的方向,但只有在對公司而言條件合適時才會採取。至少而言,這些條件包括與一家具有足夠規模與量能、能真正擴大我們推廣觸及,並且對此治療領域的病患有真正承諾的公司合作。Anaphylm 的正確道路為何,唯有時間能證明。

  • Once we have completed our Anaphylm submission to the FDA, we will also begin focusing on international markets and partnerships. Our initial focus will be to submit applications in the EU, UK, and Canada. We are exploring partnerships for ex-US commercialization of Anaphylm and expect these ex-US partnerships would contribute significantly to the company.

    在完成 Anaphylm 向 FDA 的申報後,我們也將開始把重心放在國際市場與合作夥伴關係上。我們初期將聚焦於在歐盟、英國與加拿大提交申請。我們正在探索 Anaphylm 在美國以外地區的商業化合作夥伴,並預期這些美國以外的合作將對公司帶來顯著貢獻。

  • We are also actively planning for our future. In the next quarter, we will open our Investigational New Drug Application, or IND, for AQST-108, our topical gel formulation of epinephrine. As previously discussed, we believe that AQST-108 could be extremely meaningful to the millions of patients managing alopecia areata, or AA, as well as other dermatological conditions. We expect to start our Phase IIa trial for AQST-108 in the next quarter and have some level of clinical data available to share with you before the end of this year. This timing is dependent on patient recruitment as well as our final protocol design.

    我們也在積極規劃未來。在下一季,我們將為 AQST-108(我們的腎上腺素外用凝膠配方)開啟新藥臨床試驗申請(Investigational New Drug Application,簡稱 IND)。如先前所述,我們相信 AQST-108 對於數以百萬計正在管理斑禿(alopecia areata,或 AA)以及其他皮膚科疾病的病患,可能具有極其重大的意義。我們預期在下一季啟動 AQST-108 的 IIa 期試驗,並在今年年底前提供一定程度的臨床數據與各位分享。此時程取決於病患招募以及我們最終的試驗方案設計。

  • As a reminder, an estimated 6.7 million people in the US are affected by AA. Of those affected, 43% are considered severe. The existing therapies for AA are janus kinase or JAK inhibitors. These systemic treatments with known side effects come with a black box warning and are expensive for patients. Even with these limitations, the current estimated market opportunity for JAK inhibitors is over $1 billion. As Anaphylm comes to market, if approved by the FDA, we expect AQST-108 to become our lead pipeline opportunity.

    提醒一下,估計美國有 670 萬人受到 AA 影響;其中 43% 被視為重度。目前 AA 的既有療法為 Janus 激酶(JAK)抑制劑。這些具已知副作用的全身性治療帶有黑框警語,且對病患而言費用高昂。即便有這些限制,目前 JAK 抑制劑的市場機會估計仍超過 10 億美元。隨著 Anaphylm(若獲 FDA 核准)上市,我們預期 AQST-108 將成為我們管線中最主要的機會。

  • Now, let's turn to Libervant. We were obviously disappointed by the recent Federal Court ruling that held the FDA's rationale for granting Libervant approval an orphan drug market exclusivity for underserved patients aged between two and five years was not acceptable, and we have appealed this ruling. Let's keep in mind that Libervant currently treats young, vulnerable children who have, in their case, recently been diagnosed with epilepsy, are on maintenance medication and are still at risk of seizure clusters.

    現在,讓我們談談 Libervant。我們顯然對近期聯邦法院的裁決感到失望;該裁決認為 FDA 以「孤兒藥市場獨占」授予 Libervant、用於 2 至 5 歲未被充分服務之病患的核准理由不可接受,而我們已就此裁決提出上訴。請記住,Libervant 目前治療的是年幼且脆弱的兒童;在他們的情況下,往往是近期被診斷為癲癇、正在使用維持性用藥,且仍有癲癇叢發(seizure clusters)風險。

  • We remain committed to doing everything we can to keep Libervant on the market for these young patients. We will continue to engage the FDA and the court system to protect these patients. We will keep you informed as we learn more. However, it is important to remember that in less than two years, we expect to be able to provide Libervant to all age groups regardless of any outcome in the courts.

    我們仍致力於竭盡所能,讓 Libervant 能持續為這些年幼病患提供治療並留在市場上。我們將持續與 FDA 及司法體系互動,以保護這些病患。隨著我們獲得更多資訊,將持續向各位更新。然而,重要的是要記得,在不到兩年的時間內,無論法院結果如何,我們預期都能讓所有年齡層取得 Libervant。

  • In conclusion, this is a remarkable time for Aquestive. We have more levers of growth than ever before in the history of the company. We expect to realize the following milestones in the coming months. FDA acceptance of our Anaphylm NDA submission, opening of our IND for AQST-108 and the start of our Phase IIa clinical trial, engagement with international regulatory bodies for expanding Anaphylm filings to ex US territories, continuing to build towards the commercial launch of Anaphylm if approved by the FDA and continuing to fight for patient access to Libervant.

    總結而言,這對 Aquestive 來說是個非凡的時刻。我們擁有的成長槓桿比公司歷史上任何時候都更多。我們預期在未來幾個月達成以下里程碑。FDA 受理我們的 Anaphylm NDA 申請、為 AQST-108 開啟 IND 並啟動 IIa 期臨床試驗、與國際監管機構互動以將 Anaphylm 的申報擴展至美國以外地區、若獲 FDA 核准則持續為 Anaphylm 的商業上市做準備,以及持續為病患取得 Libervant 而努力。

  • With that, I will turn the call over to Ernie.

    接下來,我把電話交給 Ernie。

  • Ernest Toth - Chief Financial Officer, Senior Vice President

    Ernest Toth - Chief Financial Officer, Senior Vice President

  • Thank you, Dan, and good morning, everyone. By now, you will have seen our financial results in our earnings release that was issued last evening. As we typically do, we will address most of the discussion related to the fourth quarter 2024 and full year 2024 results in the Q&A.

    謝謝你,Dan,各位早安。到目前為止,各位應該已在昨晚發布的財報新聞稿中看到我們的財務結果。如同我們一貫的做法,與 2024 年第四季及 2024 全年結果相關的大部分討論,我們將在問答環節中說明。

  • During 2024, we made great progress in positioning Aquestive for success. We strengthened our balance sheet by raising over $78 million in capital from high-quality institutional healthcare investors that allow continued investment in our strategic priorities, including advancing the development of Anaphylm, our lead asset, by completing all planned adult clinical trials and receiving positive feedback in the pre-NDA meeting with the FDA, having a successful pre-IND meeting for our product candidate, AQST-108, a topical gel formulation of epinephrine.

    在 2024 年,我們在為 Aquestive 的成功奠定定位方面取得了重大進展。我們透過向高品質的機構型醫療保健投資人募集超過 7,800 萬美元資金,強化了資產負債表,使我們得以持續投資於策略優先事項;其中包括推進我們的主力資產 Anaphylm 的開發,完成所有規劃的成人臨床試驗,並在與 FDA 的 NDA 前會議中獲得正面回饋;同時也就我們的產品候選藥物 AQST-108(腎上腺素外用凝膠配方)成功完成 IND 前會議。

  • Now, let's turn to the recap of our quarterly and full year financial results. Total revenue decreased to $11.9 million in the fourth quarter of 2024 from $13.2 million in the fourth quarter of 2023. This 10% decrease in revenue was primarily driven by decreases in license and royalty revenue due to $1 million of milestone royalty revenue for Azstarys from Zevra Therapeutics recognized in the prior year. Manufacture and supply revenue decreased to $10.7 million in the fourth quarter 2024 from $11 million in the fourth quarter of 2023, primarily due to a decrease in Suboxone revenues, partially offset by an increase in revenue for Ondif from Hypera. License and royalty revenue decreased to $0.8 million in the fourth quarter 2024 from $1.9 million in the fourth quarter 2023, primarily due to the previously mentioned royalty revenue for Azstarys from Zevra Therapeutics recognized in the prior year.

    現在,讓我們回顧本季與全年財務結果。2024 年第四季總營收由 2023 年第四季的 1,320 萬美元下降至 1,190 萬美元。營收下降 10% 主要是因授權與權利金收入下滑所致,原因在於前一年度認列了來自 Zevra Therapeutics 的 Azstarys 里程碑權利金收入 100 萬美元。2024 年第四季製造與供應收入由 2023 年第四季的 1,100 萬美元下降至 1,070 萬美元,主要因 Suboxone 收入下降,部分被來自 Hypera 的 Ondif 收入增加所抵銷。2024 年第四季授權與權利金收入由 2023 年第四季的 190 萬美元下降至 80 萬美元,主要因前述前一年度認列的來自 Zevra Therapeutics 的 Azstarys 權利金收入。

  • Co-development and research fees in the fourth quarter of 2024 remained relatively unchanged compared to the same period in the prior year. Total revenues increased to $57.6 million for the full year 2024 from $50.6 million for the full year 2023. This 14% increase in revenue was primarily driven by increases in license and royalty revenue due to the recognition of deferred revenue from the termination of licensing and supply agreements and increases in co-development and research fees, partially offset by decreases in manufacture and supply revenue.

    2024 年第四季共同開發與研究費用相較前一年度同期大致持平。2024 全年總營收由 2023 全年的 5,060 萬美元增加至 5,760 萬美元。營收增加 14% 主要由授權與權利金收入增加所帶動,原因包括因終止授權與供應協議而認列遞延收入,以及共同開發與研究費用增加;部分被製造與供應收入下降所抵銷。

  • Excluding this onetime recognition of deferred revenue, total revenues decreased by $4.5 million or 9% year-over-year. Manufacture and supply revenue decreased to $40 million for the full year 2024 from $43.8 million for the full year 2023, primarily due to decreases in Suboxone and Sympazan revenues, partially offset by an increase in Emylif revenues from Zambon and an increase in Ondif revenues from Hypera. Excluding a onetime retroactive price increase of $1.7 million recognized in the prior year, manufacture and supply revenue decreased to $40 million from $42.1 million.

    若排除這一次性遞延收入認列,總營收年對年減少 450 萬美元或 9%。2024 全年製造與供應收入由 2023 全年的 4,380 萬美元下降至 4,000 萬美元,主要因 Suboxone 與 Sympazan 收入下降,部分被來自 Zambon 的 Emylif 收入增加以及來自 Hypera 的 Ondif 收入增加所抵銷。若排除前一年度認列的 170 萬美元一次性追溯性調價,製造與供應收入由 4,210 萬美元下降至 4,000 萬美元。

  • Research and development expenses increased to $4.9 million in the fourth quarter 2024 from $2.9 million in the fourth quarter 2023. The increase in research and development expenses was primarily due to clinical trial costs associated with the continued advancement of the Anaphylm development program. Research and development expenses increased to $20.3 million for the full year 2024 from $13.1 million for the full year 2023. The increase in research and development expenses was primarily due to clinical trial costs and product research expenses associated with the continued advancement of both the Anaphylm and AQST-108 programs as well as increase in personnel costs and an increase in share-based compensation.

    2024 年第四季研發費用由 2023 年第四季的 290 萬美元增加至 490 萬美元。研發費用增加主要因持續推進 Anaphylm 開發計畫所產生的臨床試驗成本。2024 全年研發費用由 2023 全年的 1,310 萬美元增加至 2,030 萬美元。研發費用增加主要因持續推進 Anaphylm 與 AQST-108 兩項計畫所產生的臨床試驗成本與產品研究費用,以及人員成本增加與股份基礎給付增加。

  • Selling, general and administrative expenses increased to $16 million in the fourth quarter of 2024 from $9.6 million in the fourth quarter 2023, primarily due to increased commercial spending and regulatory fees related to the approval of Libervant for ages two to five, pre-commercial preparations for Anaphylm, severance costs of $1.8 million and higher legal expenses of $1.5 million, partially offset by a decrease in insurance fees.

    2024 年第四季的銷售、一般及行政費用由 2023 年第四季的 960 萬美元增加至 1,600 萬美元,主要由於商業支出增加,以及與 Libervant 核准用於 2 至 5 歲年齡層相關的法規費用、Anaphylm 商業化前準備、180 萬美元的資遣費用及 150 萬美元較高的法律費用所致,部分被保險費用下降所抵銷。

  • Selling, general and administrative expenses increased to $50.2 million for the full year 2024 from $31.8 million for the full year 2023. The increase was partially driven by severance costs of $2.9 million and higher personnel costs. The remainder of the increase is largely driven by higher commercial spending and regulatory fees related to the approval of Libervant for ages two to five and pre-commercial preparations for Anaphylm, partially offset by a decrease in insurance fees.

    2024 全年的銷售、一般及行政費用由 2023 全年的 3,180 萬美元增加至 5,020 萬美元。此增幅部分由 290 萬美元的資遣費用及較高的人員成本所帶動。其餘增幅主要由較高的商業支出,以及與 Libervant 核准用於 2 至 5 歲年齡層相關的法規費用與 Anaphylm 商業化前準備所致,部分被保險費用下降所抵銷。

  • Aquestive's net loss for the fourth quarter of 2024 was $17.1 million or $0.19 for both basic and diluted loss per share compared to the net loss for the fourth quarter of 2023 of $8.1 million or $0.12 for both basic and diluted loss per share. Aquestive's net loss for the full year 2024 was $44.1 million or $0.51 for both basic and diluted loss per share compared to the net loss for the full year 2023 of $7.9 million or $0.13 for both basic and diluted loss per share.

    Aquestive 於 2024 年第四季的淨損為 1,710 萬美元,基本及稀釋後每股虧損均為 0.19 美元;相較之下,2023 年第四季淨損為 810 萬美元,基本及稀釋後每股虧損均為 0.12 美元。Aquestive 於 2024 全年的淨損為 4,410 萬美元,基本及稀釋後每股虧損均為 0.51 美元;相較之下,2023 全年淨損為 790 萬美元,基本及稀釋後每股虧損均為 0.13 美元。

  • The increase in net loss for both the fourth quarter 2024 and full year 2024 was driven by increases in selling, general and administrative expenses, research and development expenses, noncash interest expense related to the amortization of the debt and royalty obligation discounts and decreases in revenues, partially offset by increases in interest income and other income and decreases in manufacture and supply expenses and loss on the extinguishment of debt.

    2024 年第四季及 2024 全年淨損增加,係由銷售、一般及行政費用、研發費用增加,與債務及權利金義務折價攤銷相關的非現金利息費用增加,以及營收下降所致;部分被利息收入及其他收入增加,以及製造與供應費用下降與債務清償損失下降所抵銷。

  • Non-GAAP adjusted EBITDA loss was $11 million in the fourth quarter 2024 compared to non-GAAP adjusted EBITDA loss of $2.8 million in the fourth quarter of 2023. Non-GAAP adjusted EBITDA loss, excluding adjusted R&D expenses, was $6.6 million in the fourth quarter 2024 compared to a non-GAAP adjusted EBITDA loss, excluding adjusted R&D expenses, of $0.1 million in the fourth quarter of 2023. Non-GAAP adjusted EBITDA loss was $23 million for the full year 2024 compared to non-GAAP adjusted EBITDA loss of $11.6 million for the full year 2023. Non-GAAP adjusted EBITDA loss, excluding adjusted R&D expenses, was $4 million for the full year 2024 compared to non-GAAP adjusted EBITDA income excluding adjusted R&D expenses of $1 million for the full year 2023.

    2024 年第四季非 GAAP 調整後 EBITDA 虧損為 1,100 萬美元,較 2023 年第四季非 GAAP 調整後 EBITDA 虧損 280 萬美元增加。扣除調整後研發費用之非 GAAP 調整後 EBITDA 虧損為 660 萬美元,較 2023 年第四季扣除調整後研發費用之非 GAAP 調整後 EBITDA 虧損 10 萬美元增加。2024 全年非 GAAP 調整後 EBITDA 虧損為 2,300 萬美元,較 2023 全年非 GAAP 調整後 EBITDA 虧損 1,160 萬美元增加。2024 全年扣除調整後研發費用之非 GAAP 調整後 EBITDA 虧損為 400 萬美元,較 2023 全年扣除調整後研發費用之非 GAAP 調整後 EBITDA 利益 100 萬美元為低。

  • As of December 31, 2024, cash and cash equivalents were $71.5 million. On a pro forma basis, the company's cash and cash equivalents were approximately $93 million adjusted for the $21.4 million raised through the company's ATM facility on February 14, 2025. The recent ATM activity continued our goal of strengthening our balance sheet as we prepare for the commercial launch of Anaphylm, if approved by the FDA. This sale of stock under the ATM facility was a result of inbound interest from two high-quality institutional health care investors, one being an existing investor. Their additional investment in Aquestive shows confidence in our story and our goal of getting products in the hands of patients.

    截至 2024 年 12 月 31 日,現金及約當現金為 7,150 萬美元。以備考(pro forma)基礎計,公司之現金及約當現金約為 9,300 萬美元,已反映公司於 2025 年 2 月 14 日透過 ATM 融資機制募集的 2,140 萬美元。近期的 ATM 活動延續我們在(若獲 FDA 核准)為 Anaphylm 商業上市做準備之際強化資產負債表的目標。此次透過 ATM 融資機制出售股票,係因兩家高品質的機構型醫療保健投資人主動表達興趣,其中一家為既有投資人。他們對 Aquestive 的加碼投資,展現對我們故事以及讓產品交付到病患手中的目標之信心。

  • Our focus in 2025 is on the advancement of our Anaphylm and AQST-108 development programs and continued commercialization of Libervant for patients ages between two and five years. As outlined in the press release issued last night after market close, our outlook for 2025 is total revenues of approximately $47 million to $56 million and non-GAAP adjusted EBITDA loss of approximately $46 million to $53 million. Our revenue guidance for 2025 includes Libervant for ages between two and five years and some level of erosion in the demand for Suboxone. As a reminder, our 2024 revenue included onetime nonrecurring recognition of deferred revenue related to the termination of certain licensing and supply agreements.

    我們 2025 年的重點在於推進 Anaphylm 與 AQST-108 的開發計畫,並持續將 Libervant 商業化以服務 2 至 5 歲的病患。如同昨晚收盤後發布的新聞稿所述,我們對 2025 年的展望為:總營收約 4,700 萬至 5,600 萬美元,非 GAAP 調整後 EBITDA 虧損約 4,600 萬至 5,300 萬美元。我們 2025 年的營收指引包含 2 至 5 歲年齡層的 Libervant,並納入 Suboxone 需求可能出現一定程度的下滑。提醒一下,我們 2024 年營收包含一次性、非經常性的遞延收入認列,該遞延收入與終止部分授權與供應協議相關。

  • Our non-GAAP adjusted EBITDA loss guidance for 2025 includes significant pre-commercial spending for Anaphylm, costs associated with the submission of the Anaphylm NDA and related filing fee, completion of the Anaphylm pediatric clinical trial, preparations for a potential advisory committee meeting, if required by the FDA, for approval of Anaphylm, commencing the AQST-108 Phase IIa clinical trial in the second quarter of 2025 and continued commercialization of Libervant for epilepsy patients between ages two and five years.

    我們 2025 年非 GAAP 調整後 EBITDA 虧損指引包含:Anaphylm 大量的商業化前支出、提交 Anaphylm NDA 及相關申請費用的成本、完成 Anaphylm 兒科臨床試驗、為可能的諮詢委員會會議(若 FDA 要求)做準備以取得 Anaphylm 核准、於 2025 年第二季啟動 AQST-108 第二期 a(Phase IIa)臨床試驗,以及持續將 Libervant 商業化以服務 2 至 5 歲的癲癇病患。

  • With that, I will now turn the line back to the operator to open the line for questions.

    接下來,我將把電話交回給接線員,開放提問。

  • Operator

    Operator

  • (Operator Instructions) Roanna Ruiz, Leerink Partners.

    (接線員指示) Roanna Ruiz,Leerink Partners。

  • Nik Gasic - Analyst

    Nik Gasic - Analyst

  • This is Nik Gasic, on for Roanna. Maybe first from us, could you remind us what are some of the key topics that the FDA might want to clarify or dig into at a potential advisory committee meeting? And what gives you confidence in Anaphylm's profile, I guess, from a PK/PD standpoint heading into this potential meeting?

    我是 Nik Gasic,代 Roanna 發言。我們先問第一個問題:您能否提醒我們,在可能召開的諮詢委員會會議上,FDA 可能希望釐清或深入探討的一些關鍵議題是什麼?另外,從藥物動力學/藥效學(PK/PD)的角度來看,您對 Anaphylm 的特性有何信心,以因應這場可能的會議?

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • Sure. Nik, nice to hear your voice. It's been an interesting process with the team here as we put the NDA together and starting to submit it to the FDA. And one of the outcomes of that is we've just continued to grow more and more constant in the profile of our product and that, that profile is the preferred and best profile for someone who is experiencing an allergic reaction.

    當然。Nik,很高興聽到你的聲音。在我們與團隊一起整理 NDA 並開始向 FDA 提交的過程中,這是一段很有意思的歷程。而其中一個結果是,我們對產品的特性愈來愈有信心;我們相信,對正在經歷過敏反應的人而言,這樣的特性是首選且最佳的。

  • And when you think about it, it's really just common sense. We all know that epinephrine stabilizes mast cells and stops mediator release. We all know that without epinephrine, mast cell degranulation accelerates, it can be life-threatening and what some of you may not know is that when there is a bad outcome from an allergic reaction that, that typically almost always happens in the first 30 minutes and that's due to a drop in blood pressure or blocked airway.

    而當你仔細想想,這其實就是常識。我們都知道腎上腺素能穩定肥大細胞並停止介質釋放。我們也都知道,若沒有腎上腺素,肥大細胞脫顆粒會加速,可能危及生命;而你們之中有些人可能不知道的是,當過敏反應出現不良結局時,通常幾乎總是發生在前 30 分鐘內,原因是血壓下降或呼吸道阻塞。

  • So when you look at our profile, we have a fast and rapid uptake of epinephrine. We have a rapid change in blood pressure. We've shown that localized epinephrine rapidly reduces mucosal edema. And we love this comparison to the products that are out there. We think the ability in that first 15 minutes to say that we are comparable to the auto-injector, it's really powerful.

    因此,當你看我們的特性時,我們的腎上腺素吸收快速且迅速。我們的血壓變化也很快。我們已證明局部給予的腎上腺素可迅速降低黏膜水腫。而我們也很喜歡與市面上既有產品做比較。我們認為,在最初 15 分鐘內能夠說我們與自動注射器(auto-injector)相當,這非常有力。

  • And we also think going, back to the common sense approach, that on an individual basis when you ask someone, what would you want? The obvious answer is, I want something that gives me enough epinephrine to ensure that I stop the allergic reaction that I have. So when we get to the AdCom, we believe that we'll have the opportunity to tell our story on our profile, and we think that will be received really very positively, not only by the AdCom, but by the other involved constituents of that day. So we're looking forward to the AdCom if it does occur.

    而我們也認為,回到常識的做法,若以個人角度問一個人:你想要什麼?顯而易見的答案是:我想要能提供足夠腎上腺素、確保我能停止目前過敏反應的東西。因此當我們進到 AdCom 時,我們相信將有機會就我們的特性把故事講清楚,而且我們認為這會獲得非常正面的回應,不僅是 AdCom,也包括當天其他相關利害關係人。所以,如果 AdCom 真的召開,我們很期待。

  • Nik Gasic - Analyst

    Nik Gasic - Analyst

  • Got it. And then maybe a second question for me. I guess like thinking ahead to a potential approval and launch, which types of patients do you think would be the early adopters of Anaphylm, or some of the other approved and commonly used epinephrine products that are out there?

    了解。接著我可能還有第二個問題。我想提前思考一下,若未來可能獲准並上市,您認為哪些類型的患者會成為 Anaphylm 的早期採用者,或是市面上其他已獲核准且常用的腎上腺素產品的早期採用者?

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • Right. Right. Well, look, I'll hand it over to Sherry in a second to give you her view. But I will fully admit my view is that anyone and everyone who is at risk of having anaphylaxis, one, should carry a rescue product; and 2, our rescue product absolutely should fit whatever profile that individual has. But I'll let Sherry give you some of her thoughts.

    對。對。嗯,這樣,我等一下先把問題交給 Sherry,請她分享她的看法。但我完全坦白,我的看法是:任何有發生過敏性休克風險的人,第一,都應該隨身攜帶急救產品;第二,我們的急救產品絕對應該符合每位個體的使用情境與需求。不過我先讓 Sherry 分享她的一些想法。

  • Sherry Korczynski - Senior Vice President, Sales and Marketing

    Sherry Korczynski - Senior Vice President, Sales and Marketing

  • Nik, nice to chat with you again. As you know, we spent a lot of time at AAAAI this past weekend, four posters, dozens of one-on-ones with key opinion leaders and allergists, and what we continue to hear over and over again is that because Anaphylm is the easiest to carry, it works so quickly and it's not a device that it has really opened the door to all patients. And so we're really excited about that from a marketing segmentation perspective, look, we definitely believe anybody -- any -- starting at the age where kids starts carrying a phone that would certainly be a primary target and then going up, but there will be lots of opportunities and options for all patients who want to carry Anaphylm.

    Nik,很高興再次和你交流。如你所知,我們上週末在 AAAAI 花了很多時間:四份海報展示、與關鍵意見領袖和過敏專科醫師進行了數十場一對一交流;而我們一再聽到的回饋是,因為 Anaphylm 最容易攜帶、起效非常快,而且它不是一個裝置(device),這確實為所有患者打開了大門。因此,從行銷分眾的角度來看,我們對此非常興奮。我們確實相信,任何人——任何——從孩子開始會帶手機的年齡起,這當然會是主要目標族群,然後再往上延伸;但對所有想攜帶 Anaphylm 的患者而言,都會有很多機會與選擇。

  • So again, we feel very strongly that it is a very broad market for Anaphylm because of how easy it is to carry and to use. And certainly, there will be certain segments that, again, teenagers, young adults, men that will certainly want to be able to have it in their pockets, in their phones very, very quickly.

    所以再次強調,我們非常堅信 Anaphylm 的市場非常廣泛,因為它非常容易攜帶且易於使用。當然,也會有某些族群——同樣地,例如青少年、年輕成人、男性——會特別希望能把它放在口袋裡、放在手機旁,並且能非常、非常快速地取用。

  • Operator

    Operator

  • (Operator Instructions) David Amsellem, Piper Sandler.

    (接線員指示) David Amsellem,Piper Sandler。

  • David Amsellem - Analyst

    David Amsellem - Analyst

  • So just got a few. First on commercialization. Just wanted to clarify, so it sounds like you are full steam ahead in terms of building your commercial infrastructure, but you are open to some sort of partnership arrangements. So I just wanted to get a sense of how likely some sort of partnership is versus just going it alone? That's number one.

    我這邊有幾個問題。第一個關於商業化。我想確認一下:聽起來你們正在全速建置商業化基礎設施,但也對某種合作夥伴安排持開放態度。所以我想了解一下:相較於單打獨鬥,你們採取某種合作的可能性有多大?這是第一個問題。

  • Number two, regarding the launch of neffy, any sort of early learnings that you gleaned from that launch in terms of how you're thinking about your opportunity, particularly interested in the extent to which the availability of neffy is expanding the market and any evidence of that? So that's number two.

    第二個,關於 neffy 的上市,你們是否從那次上市中獲得任何早期學習,進而影響你們對自身機會的思考?我特別想了解的是:neffy 的可得性在多大程度上正在擴大市場,以及是否有任何相關證據?這是第二個問題。

  • And then lastly, on Libervant, and I know I had asked this question a bunch of times, but I think it bears asking again is just how are you thinking about this asset, just given all the other things you have going on in the organization? And is that something you're looking to out-license?

    最後一個,關於 Libervant。我知道我已經問過很多次,但我覺得值得再問一次:考量到你們組織內同時在推進的其他事項,你們目前是如何看待這項資產的?以及你們是否在考慮將其對外授權(out-license)?

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • Sure. Thanks, David, and good to hear your voice. So let me first tackle your question on commercialization going it alone versus having a partner, and then I'll pass it over to Sherry, who can give you her thoughts on what she's seen with the competitor launch and your questions there.

    當然。謝謝你,David,也很高興聽到你的聲音。我先回答你關於商業化:單獨推進 versus 與夥伴合作的問題,接著我會把問題交給 Sherry,讓她分享她對競品上市的觀察,以及你相關的提問。

  • So first, as Ernie outlined in his prepared comments, our financial guidance for the year is based on us launching Anaphylm on our own. So we are investing significant time, resources, energy money in the second half of this year to make sure that we are ready to launch as soon as that approval comes through in the first quarter of 2026, which by the way, as a reminder, is before the allergy season next year. So great timing from our perspective to launch.

    首先,如 Ernie 在事先準備的發言中所概述,我們今年的財務指引是以我們自行推出 Anaphylm 為基礎。因此,我們在今年下半年投入大量時間、資源、精力與資金,確保一旦在 2026 年第一季獲得核准,我們就能立即準備好上市;順帶提醒一下,這是在明年過敏季之前。所以從我們的角度來看,上市時點非常理想。

  • The likelihood of which path we take is a really hard one, right? Because our role here as a management team is to maximize the value of Anaphylm for all stakeholders. And that value, obviously, heavily includes investors and what is good for them, but it also includes patients and making sure that we can get to the broadest scope of patients that we possibly can. So we're prepared to do that on our own, and we've lined up the plan and the spending to do that. But if the right match comes along to make us bigger, bolder and be able to get the product out further, we absolutely will engage in that. So we'll see as the months go by, and I'll keep you and everyone else as informed as I can.

    至於我們最終會走哪條路,這其實很難判斷,對吧?因為我們管理團隊的角色,是為所有利害關係人最大化 Anaphylm 的價值。而這個價值當然很大一部分包含投資人以及什麼對他們最好,但也包含患者,並確保我們能觸及盡可能廣泛的患者族群。所以我們已準備好自行推進,也已排定相應的計畫與支出。但如果出現合適的合作對象,能讓我們更強大、更有膽識,並把產品推得更遠,我們絕對會投入洽談。因此接下來幾個月我們會持續觀察,我也會盡可能讓你和大家掌握最新進展。

  • Now, let me pass it over to Sherry to talk about what she's seen with the competitor launch.

    現在我把問題交給 Sherry,請她談談她對競品上市的觀察。

  • Sherry Korczynski - Senior Vice President, Sales and Marketing

    Sherry Korczynski - Senior Vice President, Sales and Marketing

  • So as you know, and then we saw out at AAAAI this past weekend, awareness of alternatives to the needles and auto-injectors, remains key, right? It's about a strong message about what else is now available. So I would say physicians are asking the question, is the product going to work? And so that's the key.

    如你所知,而且我們上週末在 AAAAI 也看到,對於針劑與自動注射器以外替代方案的認知提升仍然是關鍵,對吧?重點在於強而有力的訊息傳遞:現在還有哪些其他選擇可用。所以我會說,醫師正在問的問題是:這個產品真的會有效嗎?而這就是關鍵。

  • We feel very strongly that we have the data, upon approval, that we will be able to share with physicians that it works. We have what I believe is the most robust package ever filed for epinephrine. We have the OASIS study that is very supportive. And so as we're seeing the ARS launch of neffy, they're driving messaging to HCPs, they'll be launching consumer campaigns.

    我們非常有信心,一旦獲准,我們將能與醫師分享數據,證明它有效。我們提交了我認為是史上最完整、最扎實的腎上腺素申報資料包。我們有 OASIS 研究提供強力支持。因此,當我們看到 ARS 推出 neffy 的上市動作時,他們正在向醫療照護專業人員(HCPs)推動訊息傳遞,也將啟動面向消費者的行銷活動。

  • And so overall, working to get the switches and build the market. That's a good thing. As it relates to neffy and ultimately to Anaphylm, the payers are the key. And so we know that it is critically important to HCPs and patients to have full access to their epinephrine product. We have heard loud and clear that Anaphylm is a game changer for patients because time is of the essence in this life-threatening situation. And physicians believe that the product will be carried more often and used earlier.

    整體而言,他們在努力促成轉換並建立市場。這是好事。就 neffy 以及最終對 Anaphylm 而言,付款方(payers)是關鍵。因此我們知道,對 HCPs 與患者來說,能夠完整取得其腎上腺素產品的給付與可近性至關重要。我們清楚聽到,Anaphylm 對患者而言是改變遊戲規則的產品,因為在這種危及生命的情況下,時間就是關鍵。而醫師也相信,患者會更常攜帶該產品,並更早使用。

  • And so it's our responsibility and why we have brought in-house expertise in our most recent hire, our new VP of Market Access, who has 25-plus years of launching 20-plus products at big and small pharma to help us do this because it is a key area of focus. We know it is for ARS, and it will be for us as well.

    因此,這是我們的責任;也正因如此,我們在最近一次招募中引進了內部專才——新任市場准入副總裁(VP of Market Access),他在大型與小型藥廠有 25 年以上經驗,曾上市 20 多項產品——來協助我們推進,因為這是我們的重點領域。我們知道這對 ARS 也同樣重要,對我們亦然。

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • And David, I think the last part of your question was on Libervant, which -- look, Libervant has, unfortunately, just time after time faced struggles that are outside of the value of the product to patients, right? I -- today, I believe in the value of Libervant for patients just as much, if not more, as they did years ago. So there will come a day where we can provide Libervant to all patients, and we look forward to that day, and we think that will be a valuable day not only for patients, but for us as an organization.

    David,我想你問題的最後一部分是關於 Libervant。你看,Libervant 很不幸地一次又一次遭遇到一些困難,而這些困難與產品對患者的價值無關,對吧?我——就今天而言——我相信 Libervant 對患者的價值,至少不亞於、甚至比多年前更高。所以終有一天,我們能把 Libervant 提供給所有患者;我們期待那一天的到來,也相信那一天不僅對患者有價值,對我們這個組織也同樣有價值。

  • In terms of where it fits in the broader strategy of Aquestive? I think, we're at an interesting crossroads right now as a company, where we have tremendous value in a variety of places. And I think it remains to be seen over the next 12 to 24 months how that value grows the company. So Libervant is important, will continue to be important and it's place in our organization, I think, will be clarified as time goes on.

    就它在 Aquestive 更廣泛策略中的定位而言?我認為,我們公司目前正處於一個很有意思的十字路口,在多個面向都擁有巨大的價值。而我認為,在未來 12 到 24 個月內,這些價值將如何推動公司成長,仍有待觀察。因此 Libervant 很重要,未來也會持續重要;而它在我們組織中的位置,我想,會隨著時間推移而更為明確。

  • Operator

    Operator

  • (Operator Instructions) Francois Brisebois, Oppenheimer.

    (接線員指示) Francois Brisebois,Oppenheimer。

  • Francois Brisebois - Analyst

    Francois Brisebois - Analyst

  • Congrats on the progress here with the submission. I just wanted to touch on something you just mentioned on David's question about the importance of the timing of the launch. Can you just help us understand what that means and how seasonality is important for this specific market? And then I have a follow-up.

    恭喜你們在這次申報上取得進展。我想稍微延伸一下你剛才在回答 David 問題時提到的:上市時點的重要性。你能否幫我們理解這代表什麼,以及季節性對這個特定市場為何重要?然後我還有一個追問。

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • Sure. Yes. Let me pass it over to Sherry, Frank.

    當然。是的。讓我把問題交給 Sherry,Frank。

  • Sherry Korczynski - Senior Vice President, Sales and Marketing

    Sherry Korczynski - Senior Vice President, Sales and Marketing

  • Frank, nice to chat with you again. Great seeing you. Look, I think that we are going to launch at a perfect time. So there is seasonality. The epinephrine market -- there is this big seasonality in the epinephrine market. So you see, and I'm sure you see from the same numbers I do, that the market starts to build in the April, May time frame, getting ready for camps. The true season begins in mid-summer and then really peaks August and September.

    Frank,很高興再次和你交流。很高興見到你。我認為我們會在一個完美的時間點上市。確實存在季節性。腎上腺素市場——腎上腺素市場有很強的季節性。所以你會看到——我相信你也看到和我相同的數據——市場會在 4 月、5 月開始升溫,為夏令營季做準備。真正的旺季從仲夏開始,並在 8 月與 9 月達到高峰。

  • So as we think about launching early -- if you assume we have a PDUFA date early February, AAAAI will be our coming out party, and we'll be right in time for the season. And especially if you think about six months in, it will be right at that time where patients are going in for their refills, getting their new prescriptions for back-to-school, and so we think it is a great timing.

    因此當我們考慮在年初上市——如果你假設我們的 PDUFA 日期在 2 月初,AAAAI 將會是我們的正式亮相,我們也將剛好趕上旺季。尤其如果你把時間往後推六個月,那正好是病患回診補領、為返校季取得新處方的時點,因此我們認為時機非常好。

  • You may be saying, well, what about payers then? Again, this is why we have brought in-house expertise to really ensure that we are working with the payers today to prepare us as best as possible for that launch, hopefully, next February of 2026.

    你可能會問,那麼付款方(payers)呢?同樣地,這也是為什麼我們引進內部專業能力,以確保我們今天就與付款方合作,盡可能為那次上市做好準備——希望是在 2026 年 2 月。

  • Francois Brisebois - Analyst

    Francois Brisebois - Analyst

  • Excellent. And then you discussed the importance of the rapid onset and being comparable to EpiPen and the importance of the start. But another topic that comes up sometimes when people think about the AdCom and what might be important and you guys have mentioned is, is on the safety front.

    很好。接著你談到快速起效的重要性、與 EpiPen 的可比性,以及起始(首劑)的重要性。但另一個有時在大家思考 AdCom 以及可能重要事項時會出現的主題——你們也提到過——是安全性面向。

  • So I was just wondering if you could share a little bit more about what makes you feel comfortable about the PK/PD profile on the safety front? And especially with emphasis on kind of the Cmax on the sales, but especially on the repeat dose, and just what makes you comfortable with those levels of epinephrine?

    所以我想請問,你們能否多分享一些,為什麼你們對 PK/PD 曲線在安全性方面感到放心?特別是針對 Cmax 的峰值,尤其是重複給藥(repeat dose)時;以及是什麼讓你們對這些腎上腺素濃度感到安心?

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • No, thanks, Frank, for that. So Sherry, said something before that I think deserves a little bit more airtime. This is the most robust package ever put together for epinephrine for the FDA. We have over 900 dosing in our film. We have twice as many subjects in our package as the competing nasal spray that was just approved. So we have a very, very robust package that we're putting in with the FDA, which has a very clean, from our perspective, AE profile and no SAEs. So when we look at the package we've created, we're very excited. And you mentioned the rapid onset with the first dose, and you really do have to start with the first dose.

    不,謝謝你提出這個問題,Frank。Sherry 先前提到的一點,我認為值得多花一些時間說明。這是迄今為止針對腎上腺素向 FDA 提交過最完整、最扎實的資料包。我們的薄膜劑型累計給藥超過 900 次。我們資料包中的受試者數量,是剛獲批的競品鼻噴劑的兩倍。因此我們向 FDA 提交的是非常、非常扎實的資料包;從我們的角度看,不良事件(AE)概況非常乾淨,且沒有嚴重不良事件(SAE)。所以當我們看著自己建立的這份資料包時,我們非常振奮。你提到首劑的快速起效,而你確實必須從首劑開始談起。

  • When you think about -- you've heard people in this space talk about this idea of bracketing to get to approval. Well, the weakness in bracketing is it allows you to be low for the first 15 or 30 minutes, if you want to be, and still get approved. We think that's the wrong profile. We think that is when mortality occurs, in fact, and Carl could tell you more if we had time. The mortality rate hasn't changed in decades. So clearly something needs to be done to make sure you get a robust enough amount of epinephrine in that first 15 or 30 minutes. So we don't -- it's interesting, as you hear comments around the space, we don't apologize for the amount of epinephrine we're giving with our first dose or our second dose, that's exactly what we think people need.

    當你想到——你也聽過這個領域的人談到所謂用「bracketing」來取得核准的概念。但 bracketing 的弱點在於:它允許你在前 15 或 30 分鐘的暴露量偏低——如果你想的話——仍然可以獲批。我們認為那是錯誤的曲線特徵。我們認為事實上死亡往往就發生在那段時間;如果時間允許,Carl 可以講更多。死亡率數十年來沒有改變。所以很明顯需要採取一些措施,確保在最初 15 或 30 分鐘內能有足夠強、足夠扎實的腎上腺素劑量。因此——很有意思的是,當你聽到這個領域的一些評論——我們不會為我們首劑或第二劑所給的腎上腺素量道歉;那正是我們認為病患所需要的。

  • So let's talk about that second dose and this supposed concern about the level of epinephrine. If you need a second dose of epinephrine, time has gone by, you are further into the disease state. The cascade of mast cell degranulation is further along, and now you're in real trouble. So you need a significant amount of epinephrine to get out of that cycle. And we think, and Carl and the team are putting everything together, we think in the AdCom that we will have a very compelling story to tell that lines up with the science and the data that we have supporting what we're -- what our profile looks like and how it is the preferred one for patients.

    那我們來談談第二劑,以及外界所謂對腎上腺素濃度的擔憂。如果你需要第二劑腎上腺素,代表時間已經過去,你已更深入進入疾病狀態。肥大細胞去顆粒化(mast cell degranulation)的連鎖反應進展得更遠,而你現在真的陷入麻煩。因此你需要相當程度的腎上腺素,才能跳脫那個循環。而我們認為——Carl 和團隊正在把所有內容整合起來——我們認為在 AdCom 上,我們將能提出一個非常有說服力的論述,與科學及我們所掌握的數據一致,來支持我們的——我們的曲線特徵長什麼樣,以及為什麼它對病患而言是更偏好的選擇。

  • Francois Brisebois - Analyst

    Francois Brisebois - Analyst

  • Okay. Great. And just maybe to finish on that, is that the level that we've seen with the curves? Is that still a physiological range of epinephrine in the body? Or are we talking about super physiological here?

    好的。很好。最後就這點再確認一下:我們在曲線上看到的那個濃度水平——那仍然是在人體內腎上腺素的生理範圍(physiological range)嗎?還是說我們談的是超生理(super physiological)?

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • Yes. So I'll pass that over to Carl to give his view.

    是的。那我把這題交給 Carl,請他分享他的看法。

  • Carl Kraus - Chief Medical Officer

    Carl Kraus - Chief Medical Officer

  • Yes. No, appreciate the question. And when you say physiologic range, obviously, the human body is well designed to address various stress states. So if you go for a run, obviously, your epinephrine levels are going to rise. And if you're resting at home, it's obviously going to go down.

    是的。不,謝謝這個問題。當你說生理範圍時,顯然人體的設計本來就能應對各種壓力狀態。所以如果你去跑步,你的腎上腺素濃度顯然會上升。而如果你在家休息,濃度顯然會下降。

  • The pharmacokinetic profile of epinephrine is such that we see linear kinetics or pharmacokinetics, but for hemodynamics and pharmacodynamics, it's not linear. I mean you reach a threshold. So whatever epinephrine levels you have in your body, at some point, trees don't grow ever taller, you don't have your heart rate, your blood pressure going ever higher. So there is a threshold that's reached, but those levels that are required to make sure you address stress situations we're built for that. I don't foresee any concerns outside the physiologic range right now.

    腎上腺素的藥物動力學特徵是:我們看到線性動力學或藥物動力學,但在血流動力學與藥效學方面並不是線性的。也就是說,你會達到一個閾值。所以不管你體內的腎上腺素濃度是多少,到了某個點,樹不會無限長高,你的心率、血壓也不會無止境地一直上升。因此會達到一個閾值;但為了確保你能應對壓力情境所需的那些濃度,我們的身體本來就是為此而打造的。就目前而言,我不預見會有超出生理範圍的疑慮。

  • Operator

    Operator

  • (Operator Instructions) Kristen Kluska, Cantor Fitzgerald.

    (接線員指示) Kristen Kluska,Cantor Fitzgerald。

  • Kristen Kluska - Analyst

    Kristen Kluska - Analyst

  • The first one is, can you speak a little bit more about some of the potential pre-AdCom work that you're doing? I think you're in a pretty unique situation having a list of all the unsolicited FDA comments from the pre-NDA meeting. Have you considered hiring any of the AdCom services or conducting a mock AdCom yourself ahead of this potential event?

    第一個問題是,你能否多談一些你們正在進行的、可能在 AdCom 之前的準備工作?我認為你們處於一個相當獨特的情況,因為你們手上有 pre-NDA 會議中 FDA 所有非主動徵詢(unsolicited)的意見清單。你們是否考慮聘請任何 AdCom 相關服務,或在這個可能的事件之前自行進行一次模擬 AdCom(mock AdCom)?

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • Yes. Thank you, Kristen. Yes, we have -- so as you know, the advisory committee process with the FDA is formulaic. So there is an order to how the day goes and every AdCom follows that process. So we have brought on external expertise to help us make sure we are ready for each section of that day.

    是的。謝謝你,Kristen。是的,我們已經——如你所知,FDA 的諮詢委員會(AdCom)流程是相當制式化的。因此,一整天的議程有固定順序,而每一場 AdCom 都會遵循該流程。所以我們引入了外部專家協助,確保我們已為當天每個環節做好準備。

  • There's already a team inside of our company that meets on a weekly basis to go through the pieces and parts, and while we don't expect the AdCom, if it occurs, to happen until the fall, we are going to be ready well in advance of that. So look, it's a lot of work for a company to get prepared. But it is -- if the AdCom occurs, it is a really nice day for us to be able to showcase all the great things about our program.

    公司內部已經有一個團隊每週開會,逐一檢視各個部分與細節;而且雖然我們不預期 AdCom(若舉行)會在秋季之前發生,但我們會在那之前很早就把一切準備就緒。所以你看,對一家公司而言,準備工作量很大。但——如果 AdCom 真的舉行——那會是我們很好的機會,向外界展示我們專案的所有亮點。

  • Kristen Kluska - Analyst

    Kristen Kluska - Analyst

  • Okay. And as you're doing a lot of the work, getting in front of physicians at conferences, et cetera, we often talk about the current EAI market. These patients obviously understand the seriousness and need to carry a form of epinephrine, but as we start thinking about the market shifting into needleless forms, how would you think in the future about penetrating into those markets where patients know that they have a serious condition, but they know that they didn't want to carry a needle, or they were afraid of a needle or it was too large, et cetera? Do you think there could be an uptick in that sale relative to what we would naturally expect as a big shift from patients also on EAIs right now?

    好的。另外,當你們做了很多工作、在各種會議上與醫師交流等等時,我們常常談到目前的 EAI 市場。這些患者顯然了解病情的嚴重性,也知道需要隨身攜帶某種形式的腎上腺素;但當我們開始思考市場轉向無針形式時,未來你會如何看待切入那些市場:患者知道自己有嚴重病況,但他們知道自己不想攜帶針具,或害怕針,或覺得裝置太大等等?你認為相較於我們自然預期(也就是目前使用 EAI 的患者大幅轉換)之外,這類銷售是否可能出現額外的上升動能?

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • Yes. Well, I'll pass it over to Sherry in a second to give her thoughts, but I'll just give one global thought, which is, as we -- again, as we've been putting the NDA together in preparing all the pieces and parts for the FDA, one thing that continues to strike me is the number of times that anaphylaxis occurs, including where there's the ultimately bad outcome of that, where the individual had never been prescribed a rescue product and didn't even know they needed a rescue product.

    是的。我先把問題交給 Sherry,請她分享看法;但我先講一個整體觀察:當我們——再次強調——在整理 NDA、為 FDA 準備所有資料與細節時,有一件事一直讓我印象深刻,就是過敏性休克發生的次數之多;其中甚至包含最終出現不良結局的案例,而當事人從未被開立過急救產品,甚至不知道自己需要急救產品。

  • So in terms of just globally, there absolutely is a need for much greater awareness to protect people. But Sherry could talk more about how that manifests itself in the marketplace.

    所以就整體而言,確實非常需要更高程度的宣導與認知提升來保護人們。但 Sherry 可以更進一步談談這在市場端會如何呈現。

  • Sherry Korczynski - Senior Vice President, Sales and Marketing

    Sherry Korczynski - Senior Vice President, Sales and Marketing

  • Kristen, nice to hear your voice. What I believe, based on all of the market research that we have been conducting, Dan mentioned, our recent ATU as well as the meetings that we are attending, and I met with dozens of physicians this past weekend one-on-one. And I think something that you'll see, and we believe will occur is -- right now, the way people are maybe looking at this, it's about a needle versus a non-needle. We believe based on our research and our conversations is this will -- the market will shift from devices versus an oral. So that's a key difference in all devices.

    Kristen,很高興聽到你的聲音。依我看,根據我們持續進行的所有市場研究——Dan 也提到我們最近的 ATU,以及我們參與的各種會議——我上週末也一對一與數十位醫師會談。我認為你會看到、而我們也相信將會發生的是——目前大家可能把這件事看成「有針」對「無針」。但根據我們的研究與對話,我們認為市場將會從「裝置」轉向「口服」。因此,這會是相較於所有裝置的一個關鍵差異。

  • And when you think about not only it's not an oral pill, it's an oral film that fits in the back of your phone. And so something that you people always have with them is their phone. And so again, I do believe this will grow because of -- it is the -- Anaphylm is the easiest to carry, it is the easiest to use, it's going to work, work quickly in that life-threatening situation. And obviously, I'm very bullish about it. And -- but I do believe we're going to see, over time, a shift from device carrying to the film or oral. So that's how I'm thinking about it, Kristen.

    而且當你想到的不只是它不是口服藥丸,而是一片口服薄膜,可以放在你手機背面。人們總是隨身帶著的就是手機。所以我再次認為,這會帶動成長,因為——Anaphylm 最容易攜帶、最容易使用,而且在那種危及生命的情況下它會起效、且起效很快。當然,我對它非常看好。而且——但我確實相信,隨著時間推移,我們會看到從攜帶裝置轉向薄膜或口服形式的轉變。所以,Kristen,我是這樣思考的。

  • Operator

    Operator

  • (Operator Instructions) Jason Butler, Citizens JMP.

    (接線員指示) Jason Butler,Citizens JMP。

  • Jason Butler - Analyst

    Jason Butler - Analyst

  • Just a couple for me. So first on Libervant. How do you think about investing in the product commercially following the court decision last month and how could that change throughout 2025? And then just on Anaphylm, can you talk about what additional awareness work you can do this year? Obviously, AAAAI was an important meeting, but what additional work you'll do to prepare for the launch?

    我這邊有兩個問題。首先關於 Libervant。在上個月法院裁決之後,你們如何看待在商業化層面對該產品的投資?而這在 2025 年期間可能會如何變化?另外關於 Anaphylm,你能談談今年還能做哪些額外的認知推廣工作嗎?顯然 AAAAI 是一個重要會議,但你們還會做哪些額外工作來為上市做準備?

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • Sure. Jason, so on Libervant, for me, the biggest thing to keep in mind on Libervant. And it's interesting in this industry. Sometimes people forget that we are -- our ultimate purpose is to actually improve patients' lives. So when I look at Libervant, we're very proud here that we have a product that we think is meaningful to patients, does save patients' lives and helps in a spot where we're talking about two- to five-year-old children.

    當然。Jason,關於 Libervant,對我而言最重要的是要記住 Libervant 的核心。而且在這個產業裡很有意思。有時候人們會忘記,我們——我們最終的目的其實是改善患者的生活。所以當我看 Libervant 時,我們在這裡非常自豪,因為我們有一個我們認為對患者很有意義的產品,確實能拯救患者生命,並且是在我們談論 2 到 5 歲兒童這個族群的情境下提供幫助。

  • So my focus right now is on making sure that we do everything we can to ensure patients in that age group who are using our product, continue to be able to use our product. Over the mid- to long term, once that's sorted out, we continue to believe that Libervant is useful and meaningful for all age groups. And you'll see us look to make sure patients have access to that.

    所以我目前的重點是確保我們竭盡所能,讓使用我們產品的該年齡層患者能夠持續使用我們的產品。在中長期,一旦這部分理順之後,我們仍然相信 Libervant 對所有年齡層都很有用、也很有意義。而你們也會看到我們會著眼於確保患者能取得該產品。

  • Now, how they have access, whether it's to your question on investing in more commercial infrastructure or partnering or finding another way to provide access to patients, we're always on every product, always looking at what's the best way to do that. But my primary focus right now is how do we make sure patients continue to have access to a product that we think is very important to them. On Anaphylm awareness and the activities that we'll be focused on this year, I'll pass it over to Sherry, again.

    至於他們如何取得——不論是你提到的加碼投資更多商業化基礎建設、或是合作夥伴模式、或是尋找其他方式來讓患者取得——我們對每一個產品都一直在評估,什麼方式最好。但我目前最主要的重點是:我們要如何確保患者能持續取得我們認為對他們非常重要的產品。至於 Anaphylm 的認知推廣與我們今年會聚焦的活動,我再交給 Sherry。

  • Sherry Korczynski - Senior Vice President, Sales and Marketing

    Sherry Korczynski - Senior Vice President, Sales and Marketing

  • Thanks, Dan. Yes. So as we mentioned, we've been to -- going to conferences, AAAAI, the college. We're doing -- we're investing significantly in our medical presence. So not only the big conferences, but dozens of regional and local conferences to ensure that the messaging is out about who is Aquestive and why Anaphylm is a game changer and will be the best choice for patients when it is available.

    謝謝,Dan。是的。如我們提到的,我們已經參加——也將持續參加各種會議:AAAAI、學會(college)。我們正在——大幅投資於我們的醫學端能見度。因此不只是大型會議,還包括數十場區域與地方型會議,以確保市場上能傳遞出訊息:誰是 Aquestive、以及為什麼 Anaphylm 是顛覆性的改變,並且在可取得時將會是患者的最佳選擇。

  • I think some other things you want to think about is, we've been conducting CME. Additionally, non-CME disease state awareness work, as I mentioned, dozens of conferences, dozens of posters, publications, medical team that is out talking to customers, KOLs, regional KOLs, so we're really working to get our messaging out.

    我想你還可以考慮其他幾點:我們一直在進行 CME。此外,還有非 CME 的疾病領域認知宣導工作;如我提到的,數十場會議、數十份海報展示、論文發表;以及我們的醫學團隊在外與客戶、KOL、區域 KOL 交流,所以我們確實在努力把訊息傳出去。

  • Another aspect of this as you prepare -- as we prepare for launch is the deep relationships we have with advocacy organization. So in the space, there's four main advocacy organizations, and based on my prior experience as well as in here at Aquestive team members, we do have significant relationships with the advocacy organization, and we will continue to be present at their event.

    在我們準備——在我們為上市做準備時,另一個面向是我們與病友倡議組織之間的深厚關係。在這個領域主要有四個倡議組織;基於我過去的經驗,以及我們這裡在 Aquestive 的團隊成員,我們與這些倡議組織確實有相當深的關係,而且我們會持續出席他們的活動。

  • Operator

    Operator

  • (Operator Instructions) Raghuram Selvaraju, H.C. Wainwright.

    (接線員指示) Raghuram Selvaraju,H.C. Wainwright。

  • Raghuram Selvaraju - Analyst

    Raghuram Selvaraju - Analyst

  • Congrats on all the recent progress. I just wanted to see if you could comment on sort of what so far has been the commercial experience with the epinephrine nasal spray? What you've been hearing with regard to whether or not that product has outperformed expectations? And in particular, if you could talk about the promotional activities that have been undertaken in support of that product and what relevance those might have to your potential future launch of Anaphylm?

    恭喜近期所有進展。我想請你們評論一下,到目前為止腎上腺素鼻噴劑在商業端的使用/銷售經驗大概如何?你們聽到的回饋是該產品是否優於預期?特別是,如果你們能談談為支持該產品所採取的推廣活動,以及這些活動對你們未來可能推出 Anaphylm 有哪些參考意義?

  • As an example, there is a fair amount of DTC activity going on in support of that product. Just wanted to see how that fits into your thinking regarding the future marketing campaign for Anaphylm as and when it gets approved. And if there's any granularity you can provide to us at this time regarding what you expect and implies promotional budget to be for a product like Anaphylm, once it is approved in the United States?

    舉例來說,針對該產品目前有相當多的 DTC(直接面向消費者)活動在進行。我只是想了解,這在你們對 Anaphylm 未來行銷活動的思考中如何定位——也就是在它獲批之後、以及何時獲批的情況下。另外,如果你們此刻能提供更細的資訊:一旦 Anaphylm 在美國獲批,你們預期像 Anaphylm 這類產品的推廣預算大概會是多少?

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • Yes. So let me give you my -- you heard Sherry's thoughts before on the space. Let me give you some of my thoughts, and Sherry can round it out, if need be. But first, on the expectations, the commercial experience and expectations from a competing product. I will leave it to our competitor to tell the space, how they feel about their performance versus expectations and don't want to shave that one way or the other for them.

    是的。那我先分享一下我的——你之前也聽過 Sherry 對這個領域的看法。我先談談我的一些想法,如有需要 Sherry 也可以補充完善。不過首先,關於市場預期、商業化經驗,以及來自競品的商業化經驗與預期。我會把這部分留給我們的競爭對手去對外說明他們如何看待自身表現相對於預期;我們不想替他們把話往任何一個方向帶。

  • What I would say in terms of the commercial experience of what we're seeing, as Sherry laid out before, there is a significant need in this space to build awareness. And so -- and that awareness is that truly is a rising tide raises all boats in this case because it is about making sure that the people who are not carrying realize there are other solutions that may bring them back into the market. The people who are carrying, but are not satisfied with their solution, showing them that there's something out there.

    就我們看到的商業化經驗而言,正如 Sherry 先前所說,這個領域在建立認知方面有很大的需求。因此——而且這種認知的提升,在這個案例中確實是「水漲船高、眾人得利」,因為重點在於讓那些沒有隨身攜帶的人意識到:還有其他解決方案,可能會讓他們回到市場。同時,對於有隨身攜帶但對現有方案不滿意的人,讓他們知道外面還有其他選擇。

  • So we -- there are big dollars being spent on awareness right now. We're very happy about that, and we hope it continues, and we think that helps everyone. We are hearing, as Sherry talked about before, that physicians want to know that the product works, and that is a difficult thing to do in a space where efficacy studies can't be performed and you're using a 505(b)(2) comparability package.

    所以——目前在提升認知上正投入大量資金。我們對此非常樂見,也希望這種投入能持續,我們認為這對所有人都有幫助。我們也聽到,如同 Sherry 先前提到的,醫師想知道產品是否有效;但在一個無法進行療效研究、且你使用的是 505(b)(2) 可比性資料套件的領域裡,這是一件很難做到的事。

  • So for us, you'll hear us this year, and we just did a AAAAI focus a lot on our OASIS study. In our OASIS study, edema was resolved, and I'm just looking at Carl to make sure I get the number right, but I believe in five minutes. So we know that we have a study that no one else has in patients who are having an allergic reaction in their oral cavity where we can show the benefit of how quickly that benefit comes through. So we're very excited about that.

    因此,就我們而言,你今年會聽到我們——而且我們剛在 AAAAI 上——非常聚焦於我們的 OASIS 研究。在 OASIS 研究中,水腫得到緩解;我只是看一下 Carl,確認我把數字說對,但我相信是五分鐘。所以我們知道,我們擁有一項其他人沒有的研究:在口腔腔內發生過敏反應的患者中,我們能展示效益,以及這個效益出現得有多快。因此我們對此非常興奮。

  • In terms of the last part of your question on DTC spend. One of the positives about a drug like Anaphylm in a space that it did is it's flexible, right? There's literally probably a mathematical equation of the more you spend, you get this; the less you spend, you get this. So we think it's a large market that as we scale and as we're able to afford bigger and bigger DTC budgets, we'll continue to grow and grow. So we won't start out with a giant DTC budget because that's just not us, and we will be respectful of the balance sheet that we have. But we think it still will be meaningful enough to get Anaphylm into a growth mode where we can continue to build it over time.

    至於你問題的最後一部分——DTC 投放。像 Anaphylm 這類藥物在其所處領域的一個優點是:它很有彈性,對吧?幾乎可以用一個數學方程式來描述:你花得越多,就得到這樣的結果;花得越少,就得到那樣的結果。所以我們認為這是一個很大的市場;隨著我們擴張、以及我們有能力負擔越來越大的 DTC 預算,我們會持續成長、再成長。因此我們不會一開始就投入巨額 DTC 預算,因為那不是我們的風格;我們也會尊重我們的資產負債表狀況。但我們認為,投入仍會有足夠的規模,讓 Anaphylm 進入成長模式,並且隨時間持續把它做大。

  • Raghuram Selvaraju - Analyst

    Raghuram Selvaraju - Analyst

  • That's very helpful. With respect to Libervant, I just wanted to clarify, the court decision, a, it seems as though the court is going off of the orphan drug exclusivity for VALTOCO, and it's not paying attention to the demarcation between the VALTOCO label and Libervant label. Is that correct?

    這非常有幫助。關於 Libervant,我想確認一下:法院的裁決,a,看起來法院是依據 VALTOCO 的孤兒藥獨占權(orphan drug exclusivity),而沒有注意到 VALTOCO 標籤與 Libervant 標籤之間的界線區分。是這樣嗎?

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • Yes. With courts, you're never really sure which way things are going to turn, right? So it's always kind of a coin toss of what a judge will do, what the appeals court will do, what the next judge will do.

    是的。在法院這種事情上,你永遠無法真正確定結果會往哪個方向走,對吧?所以某種程度上就像擲硬幣:法官會怎麼做、上訴法院會怎麼做、下一位法官又會怎麼做。

  • So look, we're -- I think the right way to think about it is we understand that Anaphylm is something we have to get filed and get through the FDA and continue to build our organization. But we think that Libervant is important to patients. And so we will continue to invest in making sure that we fight in the courts and that we get Libervant to a place where patients can continue to have access to it. Having said that, it's the court system, and you don't know until it's over.

    所以你看,我們——我認為正確的思考方式是:我們明白 Anaphylm 是我們必須完成申報、通過 FDA,並持續建置我們組織能力的項目。但我們也認為 Libervant 對患者很重要。因此我們會持續投入,確保我們在法院中奮戰,並讓 Libervant 走到一個患者能持續取得用藥的狀態。話雖如此,這是司法體系,在結束之前你不會知道結果。

  • Raghuram Selvaraju - Analyst

    Raghuram Selvaraju - Analyst

  • But in any case, just to clarify, while the appeal process is ongoing, there is no change to the authorization that Libervant currently has. Is that correct?

    不過無論如何,我只是想再確認:在上訴程序進行期間,Libervant 目前所擁有的核准/授權狀態不會有任何改變。是這樣嗎?

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • Well, that's up to the judge in the courts, right? So it depends on how they -- what their decisions are as we go through the process. So there is a broad range of outcomes that could occur. And just like all of you listening today, at some level, we're listening as well. We have to see where the judge ultimately ends up.

    嗯,那要看法院的法官怎麼決定,對吧?所以這取決於我們在程序推進過程中,他們如何——以及他們做出什麼決定。因此可能出現的結果範圍很廣。而且就像今天在聽的各位一樣,在某種程度上我們也在聽、也在等。我們必須看法官最終會怎麼裁定。

  • Raghuram Selvaraju - Analyst

    Raghuram Selvaraju - Analyst

  • And then just in terms of how long it could take for the appeals process to play out, can you just contextualize that for us in the context of the timing with which the ODE for VALTOCO is slated to expire?

    另外,就上訴程序可能需要多久才能走完,你能否在 VALTOCO 的 ODE 預計到期時間這個脈絡下,幫我們做個說明?

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • Yes. Well, look, so let's start with when the ODE for VALTOCO expires, right? That is in early 2027. So we, on a global product basis, will be ready to provide Libervant to all age groups when that day comes. And none of this court exercise will change that.

    可以。嗯,你看,我們先從 VALTOCO 的 ODE 何時到期開始,對吧?那是在 2027 年初。所以以全球產品供應的角度來看,到了那一天,我們將準備好把 Libervant 提供給所有年齡層。而這些法院程序都不會改變這一點。

  • In terms of how long an appeal process takes right now for the two- to five-year-old space on Libervant, I hate to give guidance on that. I think the courts at times can move very slowly, at times can move very fast. And all we can do is keep pushing to make sure patients have access and that's what we'll do.

    至於目前針對 Libervant 的 2 到 5 歲適應領域,上訴程序會花多久,我不太想對此給出指引。我認為法院有時候進展很慢,有時候又會很快。而我們能做的就是持續推進,確保患者能取得用藥——這就是我們會做的。

  • Raghuram Selvaraju - Analyst

    Raghuram Selvaraju - Analyst

  • Okay. Then just very quickly for Ernie. As has been the case in years past, you've provided a relatively wide top line guidance range. I was just wondering if, A, you expect as has been done previously to narrow that range as we go further into 2025. And B, if you could maybe give us some sense of what the tailwinds might be that you are factoring in to driving the company's top line performance towards the upper end of that range? In other words, what could be the factors that drive you towards that $66 million number as opposed to the $47 million number?

    好的。那再很快問 Ernie 一個問題。和過去幾年一樣,你們給出的營收(top line)指引區間相對較寬。我想請教:A,你是否預期如同以往,在 2025 年進一步推進時會縮小這個區間?以及 B,你是否能讓我們大概了解一下,你們在推動公司營收表現朝向區間上緣時,所納入考量的順風因素(tailwinds)可能有哪些?換句話說,哪些因素可能讓你們更接近 6,600 萬美元,而不是 4,700 萬美元?

  • Ernest Toth - Chief Financial Officer, Senior Vice President

    Ernest Toth - Chief Financial Officer, Senior Vice President

  • No problem. Nice to talk to you. So one thing we got to remember we do have, for this year, revenue from Libervant, 4.2 to 5 in the guide. Of course, as you just discussed about the court case, that is something that could impact the range of guidance as we move forward during the year. In addition, on Suboxone, as I mentioned in my script, there is some level of erosion that we've baked in as we usually do, whether there could be increased generic competition for Suboxone, we're just unsure of right now.

    沒問題。很高興和你交流。所以有一件事我們要記得:今年我們確實有來自 Libervant 的營收,在指引中是 420 萬到 500 萬。當然,正如你剛剛討論的法院案件,那確實可能在今年推進過程中影響指引區間。另外,關於 Suboxone,如同我在講稿中提到的,我們一如往常已經把一定程度的侵蝕(erosion)納入考量;至於 Suboxone 是否會面臨更激烈的學名藥競爭,我們目前還不確定。

  • So I think as the year progresses and we see how the market firms up for Suboxone and the orders we get from Indivior that would impact our guidance as we move forward, and we could -- we certainly would be tightening the range.

    所以我認為,隨著今年進展、我們看到 Suboxone 的市場需求轉強,以及我們從 Indivior 收到的訂單,這些都會在我們往前推進時影響我們的財測指引,而我們也——我們當然會收窄區間。

  • Operator

    Operator

  • (Operator Instructions) Gary Nachman, Raymond James.

    (接線員指示) Gary Nachman,Raymond James。

  • Gary Nachman - Analyst

    Gary Nachman - Analyst

  • Great. So back to the AdCom, as you're preparing for it, you specifically called out some decent spending behind that. Dan, it sounds like you're now leaning much more to the likelihood that you'll have the AdCom. So has there been any more guidance from FDA on that as you've been preparing the filing or are you just being extra cautious on this? And then I have some follow-ups.

    很好。那回到 AdCom,當你們在準備時,你們特別提到在這方面會有相當不錯的支出。Dan,聽起來你現在更傾向於 AdCom 很可能會召開。所以在你們準備送件的過程中,FDA 是否有提供更多指引,還是你們只是特別保守?另外我還有一些追問。

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • Yes. Gary, yes, we have no additional insight from the FDA. We are we're doing what good stewards of a company should do and preparing without thought of whether it will or will not happen. And obviously, ultimately, it's up to the FDA whether they decide to have it or not.

    是的。Gary,是的,我們沒有從 FDA 得到任何額外的訊息。我們是在做一家公司的良好管理者應該做的事:不去預設它會或不會發生,而是做好準備。而且很明顯,最終是否召開取決於 FDA 的決定。

  • Gary Nachman - Analyst

    Gary Nachman - Analyst

  • Okay. And then you said you saw some initial data from the pediatric study for Anaphylm that you said was in line with expectations. Any more color on that? And when will you have the final data just to ensure there are no issues there for the filing?

    了解。另外你提到你們看到 Anaphylm 的兒科研究一些初步數據,並表示符合預期。能否再多補充一些細節?以及你們何時會拿到最終數據,以確保送件不會有任何問題?

  • And then on commercial, if you end up commercializing Anaphylm on your own, how many reps will you need? And then how quickly will you be able to get them on board after the approval to launch very quickly there?

    再來在商業化方面,如果最後你們選擇自行商業化 Anaphylm,你們需要多少位業務代表?以及在核准後,你們能多快把人員招募到位,以便非常快速地上市?

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • Right. Well, I'll pass it over to Carl in a second. I know he's been dying to jump in on the pediatric study. So thank you for that question, but I'll just give a timing answer. In terms of the pediatric data, we have a big chunk of it right now. We're getting more shortly.

    好的。我等一下把問題交給 Carl。我知道他一直很想就兒科研究跳進來回答。所以謝謝你這個問題,但我先回答時間點。就兒科數據而言,我們目前已經拿到其中很大一部分。我們很快也會再收到更多。

  • And in terms of making sure it gets into the NDA, we have that timing mapped out so that there's no issue. But I'll let Carl give you his thoughts on what he's seeing.

    至於確保能納入 NDA,我們已把時程規劃好,因此不會有問題。不過我讓 Carl 分享他看到的情況。

  • Carl Kraus - Chief Medical Officer

    Carl Kraus - Chief Medical Officer

  • Yes. No, I appreciate the question. And as Dan already stated, the intention is to provide the necessary elements of the pediatric study into the filing that is certainly completely on schedule. The profiles we're seeing from the pediatric study are completely in accord with our expectations and for the requirement of submitting the filing as already stated, we will have the necessary data from the pediatric study to support it. So we're extremely pleased not only with the timing, but also the data that we're seeing coming out of that study.

    是的。不,我很感謝這個問題。如 Dan 已經提到,我們的目標是把兒科研究所需的要素納入送件,而且時程絕對完全按計畫進行。我們在兒科研究看到的特徵(profile)完全符合我們的預期;而就送件要求而言,如先前所述,我們將會取得支持送件所需的兒科研究必要數據。所以我們不僅對時程非常滿意,也對該研究產出的數據非常滿意。

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • And I think the next part of your question, Gary, was on the number of reps. I'll let Sherry give you her thoughts on how she would build up to the right amount. But just as a reminder, we've given clear guidance, we will not hire a single sales rep until after approval, but Sherry can take it from there.

    我想你問題的下一部分,Gary,是關於業務代表的人數。我讓 Sherry 分享她會如何把團隊擴編到合適規模。但提醒一下,我們已給出明確指引:在核准之前,我們不會聘用任何一位銷售代表;不過 Sherry 可以接著說。

  • Sherry Korczynski - Senior Vice President, Sales and Marketing

    Sherry Korczynski - Senior Vice President, Sales and Marketing

  • Thanks, Gary. Nice to hear your voice. As you think about the number of allergists that are practicing as well as some very kind of high decile pediatricians, some PCPs and nurse practitioner PAs, we believe in that around 100 mark is a good number for us to start with as far as the sales force. May go up, may go down, may phase in folks. But overall, to cover the most important customers, I think we're at a sweet spot of about 100. So that's first and foremost.

    謝謝你,Gary。很高興聽到你的聲音。考量到執業的過敏專科醫師數量,以及一些處於高分位(high decile)的兒科醫師、部分 PCP(基層照護醫師)與護理師執業者/醫師助理(NP/PA),我們認為以大約 100 人左右作為銷售團隊的起步規模是合適的。可能會增加、可能會減少,也可能分階段導入人員。但整體而言,為了覆蓋最重要的客戶,我認為大約 100 人是我們的甜蜜點。這是最主要的。

  • And as Dan mentioned, we would not make offers until after approval. However, we will spend a good deal of time in Q4 preparing to make those hires, so that upon approval, we would be ready to hire the reps.

    如 Dan 所提到,我們在核准之前不會提出聘用邀約。不過,我們會在第四季投入相當多時間準備招募,讓我們在核准後就能立即準備好聘用業務代表。

  • Gary Nachman - Analyst

    Gary Nachman - Analyst

  • Okay. And then just last question back on the partnership discussions that you're having. Is it possible that you could have a full global partner for Anaphylm or that it would more likely be split up by geography, US versus ex US?

    了解。最後一個問題回到你們正在進行的合作夥伴討論。Anaphylm 是否有可能找到一個完整的全球合作夥伴,或更可能按地理區域拆分,例如美國與美國以外?

  • And then, Dan, maybe you could just give a little bit of color just the type of partnership that you think would make sense. It's probably a lot of different iterations there. But if you do sign someone in the US and you decide to go down that test, what do you think that might look like? And are you really leaning towards having a co-co where you would also have a commercial presence. Is that an important piece of it?

    另外,Dan,也許你可以再補充一些你認為合理的合作型態。可能有很多不同的組合。但如果你們在美國簽下一家夥伴並決定走那條路,你覺得可能會是什麼樣子?以及你們是否真的傾向採用共同商業化(co-co),也就是你們同時保有商業團隊的存在。這是否是其中重要的一環?

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • Yes. Now, for the US, in particular, we will not comment. So we are -- we will not -- if we were to partner with someone, we will not partner with someone unless, as I said in my prepared remarks, they have a significant muscle to help us and that they have a significant commitment to the therapeutic space. So those are entry criteria for talking with us that we will not waver from.

    是的。就美國而言,我們不會評論。所以我們——我們不會——如果要與某方合作,除非如我在事先準備的發言中所說,他們具備能協助我們的顯著實力(muscle),並且對該治療領域有重大的投入承諾,否則我們不會與其合作。因此,這些是與我們洽談的入門條件,我們不會在這些條件上讓步。

  • In terms of whether it ultimately, we find a global partner or a US partner if we go down that path, I think there are large companies that fit both of the criteria I laid out that could be both global or just US. So I think both of those are available. I do want to just remind everyone that ex US, we clearly -- in the US, it's more about what's the right path for getting Anaphylm to everyone. Outside the US, we will be on a partnership-only approach. So a little bit of a nuance between those two positions.

    至於最終我們是否會找到全球合作夥伴,或如果我們走那條路而找到美國合作夥伴,我認為有一些大型公司符合我剛才提出的兩項標準,既可能是全球型,也可能只涵蓋美國。所以我認為兩種選項都存在。我也想提醒大家,美國以外(ex US)方面我們很清楚——在美國,更多是在於選擇讓 Anaphylm 觸及所有人的正確路徑。在美國以外,我們將採取僅透過合作夥伴(partnership-only)的策略。所以這兩個立場之間有一點細微差別。

  • Gary Nachman - Analyst

    Gary Nachman - Analyst

  • Okay. And I mean, just in terms of timing, I know this might be a difficult question to answer. But do you think you could have a partnership in place before there would be an AdCom, if there is an AdCom? Just because you are spending a lot behind all your prelaunch activities, so you have to manage that with the possibility that you could have a partner that would share in that. So is it reasonable to think that people would want more visibility on the path forward? Or do you think there's enough there where you could potentially execute it sooner?

    了解。就時程而言,我知道這可能很難回答。但你認為在可能的 AdCom 之前(如果真的有 AdCom),你們有機會把合作夥伴安排到位嗎?因為你們在所有上市前活動上投入很多支出,所以你們必須在這些支出與可能由合作夥伴分攤之間做管理。所以認為對方會想要對未來路徑有更高能見度,這樣的想法合理嗎?或者你覺得目前資訊已足夠,使你們可能更早就能推進並完成?

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • Yes, Gary, you and I have known each other a long time, right? I learned long ago, you don't run a business based on trying to do something by a date, right? So we're not focused on any particular date or any moment in time or inflection point of you have to do something here or not do something.

    是的,Gary,你我認識很久了,對吧?我很早就學到一件事:你不會為了某個日期去經營一家公司,對吧?所以我們不會聚焦在任何特定日期、任何特定時間點或拐點,覺得你必須在這裡做或不做某件事。

  • We have our path, we have our plan, we're very fortunate to have not only Sherry, but people under Sherry who are very talented. We're more than happy to bring this to market ourselves. And if the right partner comes along that can augment our ability, we'll do that. If they don't, we won't. So there's no timing element to that, that we will force ourselves or anyone else to.

    我們有我們的路徑,我們有我們的計畫;我們非常幸運,不僅有 Sherry,Sherry 底下也有非常有才華的人。我們非常樂意自行把產品推向市場。如果有合適的合作夥伴出現,能夠強化我們的能力,我們就會合作。如果沒有,我們就不會。所以這件事沒有任何我們會強迫自己或強迫任何人的時間因素。

  • Operator

    Operator

  • (Operator Instructions) Thomas Flaten, Lake Street Capital Markets.

    (接線員指示) Thomas Flaten,Lake Street Capital Markets。

  • Thomas Flaten - Analyst

    Thomas Flaten - Analyst

  • Just a follow-up on a couple of questions that have been asked already. Sherry, back to the hiring of the sales force and the very peculiar seasonality associated with this type of product, when would be the optimal time then assuming a February PDUFA date, like you had said in an earlier response, would you want to have those reps out in the field?

    就先前已經被問到的幾個問題再追問一下。Sherry,回到銷售團隊的招募,以及這類產品非常特殊的季節性;假設如你先前回覆所說 PDUFA 日期在二月,那麼最佳時點會是何時?你會希望那些業務代表何時開始在外勤跑市場?

  • Sherry Korczynski - Senior Vice President, Sales and Marketing

    Sherry Korczynski - Senior Vice President, Sales and Marketing

  • Almost immediately. So if you think about, if we're in early phase, you just assume early February, you have AAAAI at the end of February of 2026, and so -- and the season starts to ramp up and so yes, we would look to do all the preparation work prior to the PDUFA and then hire the reps immediately thereafter.

    幾乎是立刻。所以如果你想像一下,假設我們處於早期階段,就先假設是二月初;2026 年二月底有 AAAAI,然後——季節也開始升溫;所以是的,我們會在 PDUFA 之前完成所有準備工作,並在其後立即招募業務代表。

  • Thomas Flaten - Analyst

    Thomas Flaten - Analyst

  • Got it. And then, Dan, just to clarify, given the pediatric data, how many presentations of the product will there be -- how many dosage forms will you actually have available for prescribing once the product is approved?

    了解。然後 Dan,再確認一下:考量到兒科數據,產品會有多少種規格——也就是一旦產品獲批後,實際上可供開立處方的劑型/劑量形式會有幾種?

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • Yes. So the initial approval will be for patients 30 kilos and up, which is about seven years of age. And that will be comparable to the adult dose of the EpiPen, the adult (inaudible) down to 30. So that's just one dose. We will, after that, just like the other companies around us, put a junior dose through its paces with the FDA and bring that to market. So at launch next spring, there will be one dose. Over time as we take a view of the whole market, there will ultimately be two doses.

    是的。所以初始核准將適用於體重 30 公斤以上的患者,大約是 7 歲左右。而這將可比於 EpiPen 的成人劑量,也就是成人(聽不清)一直到 30 公斤。所以那就只有一種劑量。之後,我們會像周邊其他公司一樣,讓兒童(junior)劑量走完與 FDA 的流程,並把它推向市場。因此在明年春季上市時,會是一種劑量。隨著時間推進、我們從整體市場角度來看,最終會有兩種劑量。

  • Operator

    Operator

  • (Operator Instructions) James Molloy, Alliance Global Partners.

    (接線員指示) James Molloy,Alliance Global Partners。

  • James Molloy - Analyst

    James Molloy - Analyst

  • Ernie, just a quick one on the -- this may tie into the partnership question that was just asked earlier. When you look at the $16 million G&A spend in the fourth quarter, is that the level we should be looking at going forward? Is that dependent upon whether or not you're going to have a partner to -- for Anaphylm or is that number going to be going doubling, going back to the 12 level through '25?

    Ernie,我這邊快速問一個——這可能也和剛才提到的合作夥伴問題有關。當你看到第四季 1,600 萬美元的 G&A 支出時,這會是我們往後應該預期的水準嗎?這是否取決於你們是否會為 Anaphylm 找到合作夥伴——或者這個數字會翻倍,回到 2025 年期間約 1,200 萬的水準?

  • Ernest Toth - Chief Financial Officer, Senior Vice President

    Ernest Toth - Chief Financial Officer, Senior Vice President

  • Well, one thing in the -- Jim, in the fourth quarter, there was a severance charge in there. So that inflated somewhat of the fourth quarter. But looking forward to '25, as I said in my prepared remarks on our guidance, we have included amounts for the pre-commercial work for Anaphylm, some of which Sherry has alluded to earlier in her comments, we are continuing to commercialize Libervant. And so we would see some increase in our SG&A, most likely in the second half of the year is where it will be more heavily weighted as we prepare for -- as we continue all the pre-commercial work for Anaphylm.

    嗯,有一點是——Jim,在第四季裡面有一筆資遣費用。所以第四季的數字被稍微墊高了。但展望 2025 年,正如我在事先準備的指引說明中提到的,我們已納入 Anaphylm 商業化前置工作的相關金額,其中一部分 Sherry 先前在她的評論中也提到;我們也持續推進 Libervant 的商業化。因此我們預期 SG&A 會有一些增加,最可能是在下半年權重較高,因為我們在準備——也就是在持續進行 Anaphylm 的所有商業化前置工作。

  • James Molloy - Analyst

    James Molloy - Analyst

  • Great. And then last question for me then on the Libervant. Any risk in marketing Libervant, given with this ruling out there? I know it was touched upon that you don't really know what's going to happen with the courts. But if -- any thoughts on timing and any risk you might have on still marketing Libervant given this recent ruling?

    很好。那我最後一個問題是關於 Libervant。鑑於目前有這項裁定,行銷 Libervant 是否有任何風險?我知道剛才有提到你們其實也不確定法院會怎麼走。但——對於時程以及在這項最新裁定之下仍持續行銷 Libervant,你們是否有任何想法、以及可能面臨的風險?

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • Yes. Look, the risk on marketing Libervant is completely the court system. So similar to my answer to Gary on timing of, if we were to partner Anaphylm, it's similar with Libervant with the courts. There are certain things we can control in this universe, and the court system timing and the court system decision is not one of those. So we will -- we're committed to patients in this space. We think our product is important. We think it's important to patients. We'll continue to fight and advocate for them, and we'll see what happens.

    是的。你看,行銷 Libervant 的風險完全在於法院體系。所以就像我先前回答 Gary 關於時程、如果我們要為 Anaphylm 找合作夥伴的問題一樣;Libervant 也同樣取決於法院。在這個範疇裡,有些事情我們能掌控,而法院體系的時程與法院的裁決並不在其中。所以我們會——我們對這個領域的患者有承諾。我們認為我們的產品很重要。我們認為它對患者很重要。我們會持續為他們奮戰並為他們發聲,然後看看結果如何。

  • Operator

    Operator

  • I'm not showing any further questions at this time. I'd like to turn the call back over to Daniel Barber, CEO, for any closing comments.

    目前我這邊沒有看到其他問題。我想把電話會議交回給執行長 Daniel Barber,請他做結語。

  • Daniel Barber - President, Chief Executive Officer, Director

    Daniel Barber - President, Chief Executive Officer, Director

  • Thanks, Kevin. Thank you for joining us this morning. As you heard today, we're incredibly excited about the progress the company has made, and we believe we are well positioned for a successful 2025. We look forward to the next time we interact. And with that, I wish all of you a wonderful day.

    謝謝你,Kevin。感謝各位今天早上加入我們。如各位今天所聽到的,我們對公司所取得的進展感到非常振奮,並相信我們已為 2025 年的成功做好充分準備。我們期待下次再與各位交流。最後,祝各位有美好的一天。

  • Operator

    Operator

  • Thank you, ladies and gentlemen. This does conclude today's presentation. You may now disconnect, and have a wonderful day.

    謝謝各位女士、先生。今天的簡報到此結束。各位現在可以掛線,祝各位有美好的一天。